1. Home
  2. MRKR vs ABLV Comparison

MRKR vs ABLV Comparison

Compare MRKR & ABLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MRKR
  • ABLV
  • Stock Information
  • Founded
  • MRKR N/A
  • ABLV 2015
  • Country
  • MRKR United States
  • ABLV China
  • Employees
  • MRKR N/A
  • ABLV N/A
  • Industry
  • MRKR Biotechnology: Pharmaceutical Preparations
  • ABLV
  • Sector
  • MRKR Health Care
  • ABLV
  • Exchange
  • MRKR Nasdaq
  • ABLV Nasdaq
  • Market Cap
  • MRKR 35.8M
  • ABLV 38.1M
  • IPO Year
  • MRKR N/A
  • ABLV N/A
  • Fundamental
  • Price
  • MRKR $3.10
  • ABLV $0.90
  • Analyst Decision
  • MRKR Strong Buy
  • ABLV
  • Analyst Count
  • MRKR 1
  • ABLV 0
  • Target Price
  • MRKR $19.00
  • ABLV N/A
  • AVG Volume (30 Days)
  • MRKR 26.1K
  • ABLV 15.7K
  • Earning Date
  • MRKR 11-14-2024
  • ABLV 01-01-0001
  • Dividend Yield
  • MRKR N/A
  • ABLV N/A
  • EPS Growth
  • MRKR N/A
  • ABLV 18.07
  • EPS
  • MRKR N/A
  • ABLV 0.24
  • Revenue
  • MRKR $5,395,849.00
  • ABLV $148,999,819.00
  • Revenue This Year
  • MRKR $35.94
  • ABLV N/A
  • Revenue Next Year
  • MRKR N/A
  • ABLV N/A
  • P/E Ratio
  • MRKR N/A
  • ABLV $3.59
  • Revenue Growth
  • MRKR 79.04
  • ABLV 2.58
  • 52 Week Low
  • MRKR $2.44
  • ABLV $0.67
  • 52 Week High
  • MRKR $6.16
  • ABLV $3.94
  • Technical
  • Relative Strength Index (RSI)
  • MRKR 42.91
  • ABLV 48.58
  • Support Level
  • MRKR $2.91
  • ABLV $0.82
  • Resistance Level
  • MRKR $3.25
  • ABLV $0.93
  • Average True Range (ATR)
  • MRKR 0.38
  • ABLV 0.07
  • MACD
  • MRKR -0.11
  • ABLV 0.00
  • Stochastic Oscillator
  • MRKR 17.72
  • ABLV 53.00

About MRKR Marker Therapeutics Inc.

Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. It is also developing peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors, as well as PolyStart.

About ABLV Able View Global Inc.

Able View Global Inc operates as a brand management partner of international beauty and personal care brands in China. It provides full-service solutions covering marketing plan, branding, digital and social marketing, omni-channel sales, customer service, overseas logistics, warehouse, and fulfillment. The firm generates revenue from product sales by distributing and selling cross-border products from various brand owners to Chinese consumers.

Share on Social Networks: